Affiliation:
1. City Mariinsky Hospital
Abstract
Multiple myeloma (MM) is a malignant immunoproliferative disease involving plasma cells, leading to their malignant proliferation and the production of monoclonal paraproteins. Intracranial tumor spread in MM is very rare. This is a unique and infrequent localization, which makes it difficult to diagnose the disease. We report a rare case of treatment of a patient with MM intracranial spread, whose disease was presumably in remission and recurred as an intracranial plasmacytoma with a clinical picture of acute cerebrovascular accident. Surgical intervention was performed to remove the tumor, a histopathological analysis of the removed tissue was carried out. Even with early diagnosis, the prognosis remains bleak, with median survival rates of 3 to 6 months. However, aggressive multimodal treatment can prolong life by months.
Reference13 articles.
1. Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology. 2014; 15(12): e538–48a. https://doi.org/10.1016/S1470-2045(14)70442-5.
2. Firsova MV, Mendeleeva LP, Kovrigina AM, et al. Clinical features of the extramedullary disease in multiple myeloma. Russian Journal of Hematology and Transfusiology. 2017; 62(2): 75–82 (in Russ.).
3. Firsova MV, Mendeleeva LP, Kovrigina AM, et al. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. BMC Cancer. 2020; 20: 346. https://doi.org/10.1186/s12885-020-06870-w.
4. Touzeau С, Moreau P. How I treat extramedullary myeloma. Blood. 2016; 127(8): 971–6. https://doi.org/10.1182/blood-2015-07-635383.
5. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Ann Rev Pathol. 2011; 6: 249–74. https://doi.org/10.1146/annurev-pathol-011110-130249.